Trial · NCT05073692
Comparison of Type 2 Diabetes Pharmacotherapy Regimens
NCT05073692, Completed, Kaiser Permanente; results first posted 2025-11-21
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Comparison of Type 2 Diabetes Pharmacotherapy Regimens. Trials, record NCT05073692. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05073692
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Comparison of Type 2 Diabetes Pharmacotherapy Regimens
- NCT number
- NCT05073692
- Status
- Completed
- Enrollment
- 241,981 participants, actual
- Lead sponsor
- Kaiser Permanente
- Conditions
- Type 2 Diabetes Mellitus, Cardiovascular Diseases
- Interventions
SU, DPP4, SGLT2i, GLP-1RA, SGLT2i or GLP-1RA, Linagliptin (DPP4), Exenatide (GLP-1RA), Liraglutide (GLP-1RA), Empagliflozin (SGLT2i), Glimepiride (SU), Glipizide (SU), Glimepiride (SU) or Glipizide (SU), SU or DPP4 (excluding saxagliptin and alogliptin), Exenatide (GLP-1RA) or Liraglutide (GLP-1RA)
- First posted
- 2021-10-11
- Last updated
- 2025-11-21
- Results first posted
- 2025-11-21
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of 3-point Major Adverse Cardiovascular Events (MACE) | 2.5 years | 3-point MACE is defined as a single outcome measure, which is a composite measure of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular disease death. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Incidence of 3-point Major Adverse Cardiovascular Events (MACE) | 2.5 years | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Incidence of 3-point Major Adverse Cardiovascular Events (MACE) | SU Initiators | 11,348 | Participants | ||
| Incidence of 3-point Major Adverse Cardiovascular Events (MACE) | DPP4 Initiators | 393 | Participants | ||
| Incidence of 3-point Major Adverse Cardiovascular Events (MACE) | SGLT2i Initiators | 424 | Participants | ||
| Incidence of 3-point Major Adverse Cardiovascular Events (MACE) | GLP-1RA Initiators | 296 | Participants |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | SU Initiators | 212,042 | |
| Overall Study | STARTED | DPP4 Initiators | 5,862 | |
| Overall Study | STARTED | SGLT2i Initiators | 14,858 | |
| Overall Study | STARTED | GLP-1RA Initiators | 9,219 | |
| Overall Study | COMPLETED | SU Initiators | 169,348 | |
| Overall Study | COMPLETED | DPP4 Initiators | 4,402 | |
| Overall Study | COMPLETED | SGLT2i Initiators | 13,681 | |
| Overall Study | COMPLETED | GLP-1RA Initiators | 7,863 | |
| Overall Study | NOT COMPLETED | SU Initiators | 42,694 | |
| Overall Study | NOT COMPLETED | DPP4 Initiators | 1,460 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals12
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | SU Initiators | 4,867 | 212,042 |
| Total, all-cause mortality | DPP4 Initiators | 235 | 5,862 |
| Total, all-cause mortality | SGLT2i Initiators | 117 | 14,858 |
| Total, all-cause mortality | GLP-1RA Initiators | 109 | 9,219 |
| Total, other adverse events | SU Initiators | 0 | 0 |
| Total, other adverse events | DPP4 Initiators | 0 | 0 |
| Total, other adverse events | SGLT2i Initiators | 0 | 0 |
| Total, other adverse events | GLP-1RA Initiators | 0 | 0 |
| Total, serious adverse events | SU Initiators | 0 | 0 |
| Total, serious adverse events | DPP4 Initiators | 0 | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse event totalsPapers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05073692
GET https://conductscience.org/api/trials/v1/NCT05073692/registered